Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

J. B. Chemicals & Pharmaceuticals Limited manufactures and markets pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients (API) in India and internationally. The company's API product portfolio includes diclofenac sodium, diethylamine, acid, and potassium; nifedipine, atenolol, and cilnidipine; and ciprofloxacin, cetirizine, and meclizine HCI. It also provides dosage forms, such as tablets, lozenges, injectables, gels, creams, ointments, liquid herbal syrups, cold rubs, eye drops, troches, and capsules; and soft-centered, powder, medicated, and herbal lozenges, as well as various pharmaceutical dosage forms. In addition, it offers a range of contrast media products, including x-ray, magnetic resonance imaging (MRI), and ultrasound scanners; and contract manufacturing services. The company provides its products in gastroenterology, anti-infectives, wound care, neonatology and pediatrics, gynaecology, dental, vitamins and minerals, hypertension, diabetes, nephrology, respiratory, pain-analgesic, dermatology, antivirals, lozenges, and contrast media and radio diagnostic therapeutic areas. J. B. Chemicals & Pharmaceuticals Limited was incorporated in 1976 and is headquartered in Mumbai, India.

Revenue projections:

Revenue projections for JBCHEPHARM
Revenue projections for JBCHEPHARM

The projected decline in JBCHEPHARM's revenues compared to last year is expected to make investors cautious. A drop in revenue often has a direct negative effect on the company's bottom line, signaling potential challenges that could undermine investor confidence and reduce overall profitability.

Financial Ratios:

currentRatio 0.000000
forwardPE 30.806557
debtToEquity 1.075000
earningsGrowth 0.216000
revenueGrowth 0.105000
grossMargins 0.670510
operatingMargins 0.235240
trailingEps 47.440000
forwardEps 59.922310

With both earnings and revenue growth showing positive trends, J. B. Chemicals & Pharmaceuticals Limited is expected to expand its business. This signals a healthy financial trajectory, suggesting that the company is positioned for continued growth and increasing profitability.
Positive gross and operating margins for JBCHEPHARM suggest that the company is operating profitably. These margins highlight JBCHEPHARM's efficiency in managing costs while maintaining healthy revenue streams, contributing to its overall financial strength.
JBCHEPHARM's forward EPS surpasses its trailing EPS, reflecting expectations of higher profitability in the current year. This suggests that JBCHEPHARM is projected to generate stronger earnings, indicating an optimistic financial outlook compared to the prior year's results.

Price projections:

Price projections for JBCHEPHARM
Price projections for JBCHEPHARM

J. B. Chemicals & Pharmaceuticals Limited's price has consistently hovered near the lower end of price projections. This trend suggests that the stock is underperforming relative to analyst expectations, indicating a potential lack of momentum for upward movement in the near future.

Insider Transactions:

Insider Transactions for JBCHEPHARM
Insider Transactions for JBCHEPHARM


72 JBCHEPHARM sales were executed, with market price at 1730.9479200575088.1 purchases of JBCHEPHARM stock were recorded, with market price of 1884.5999755859375 per share.JBCHEPHARM is seeing more buys than sells at current price levels, which may indicate a positive market outlook. This trend suggests growing confidence among investors, who appear to expect favorable performance from the stock.

Recommendation changes over time:

Recommendations trend for JBCHEPHARM
Recommendations trend for JBCHEPHARM


J. B. Chemicals & Pharmaceuticals Limited has received a favorable buy bias from analysts recently, positioning it as a solid investment opportunity. This sentiment may attract more investors, who view J. B. Chemicals & Pharmaceuticals Limited as a stable option to park their money and potentially benefit from the company's continued growth and profitability.